Urological Cancer Market Forecast Grow at a Compound Annual (CAGR) of 10.39%, from $17.9 billion in 2015 to $35.9 billion in 2022

1
Global Urological Cancer Market to 2022 - Strong
Growth Driven by Rising Prevalence Increased
Uptake of Hormone Therapies and Approval of Novel
Biologics
TELEPHONE [phone]E-MAIL
sales_at_researchbeam.com
2
Report Overview
Urological cancers are thought to account for
19.5 of global cancer prevalence, with kidney,
prostate, testicular and bladder cancer - the key
indications covered in this report - accounting
for the majority of that figure. Urological
cancers affect the male and female urinary tract
and the male reproductive organs. Prostate cancer
is the most prevalent of these malignancies. A
number of common etiologic factors have been
strongly characterized as raising the risk of
developing urological cancers, including age,
chronic inflammation, gender, obesity, tobacco
usage and heritable cancer syndromes. The risk of
cancer increases greatly in patients over the age
of 65. Populations in developed countries are
projected to become increasingly aged and show
rising obesity incidence, which will drive both
cancer prevalence and revenue growth for its
treatments. Hormone therapies for prostate
cancers and angiogenesis inhibitors for renal
cell carcinoma are currently the most
commercially successful urological cancer drugs.
However, there has been a shift towards the
clinical testing of cancer immunotherapies - such
as Opdivo, which was recently approved for renal
cell carcinoma.
RESEARCH
No of Pages 250

3
Report Overview
Scope- Global revenues for the urological cancer
market are forecast to grow at a Compound Annual
Growth Rate (CAGR) of 10.39, from 17.9 billion
in 2015 to 35.9 billion in 2022. Which drugs
will achieve blockbuster status and how will the
key player companies perform during the forecast
period? - The urologic oncology pipeline is large
and diverse, and contains 817 products. How does
the composition of the pipeline compare with that
of the existing market? Reasons to buy-
Understand the current clinical and commercial
landscape by considering disease pathogenesis,
diagnosis, prognosis, and the treatment options
available at each stage of diagnosis - Visualize
the composition of the urological cancer market
across each indication, in terms of dominant
molecule types and targets, highlighting the key
commercial assets and players - Analyze the
urological cancer pipeline and stratify by stage
of development, molecule type and molecular
target, with a granular breakdown across key
indications
RESEARCH
No of Pages 250

4
Table of Content
1 Table of Contents 2 Introduction 92.1 Disease
Cluster Introduction 92.2 Symptoms 92.3
Etiology and Pathophysiology 103 Key Marketed
Products 233.1 Overview 234 Pipeline Landscape
Assessment 355 Multi-Scenario Market Forecast to
2022 705.1 Overall Market Size 705.2 Generic
Penetration 725.3 Revenue Forecast by Molecular
Target 756 Company Analysis and Positioning
806.1 Revenue and Market Share Analysis by
Company 817 Strategic Consolidations 95 8
Appendix 107 Enquire Heregtgtgt http//www.researchbe
am.com/global-urological-cancer-to-2022-strong-gro
wth-driven-by-rising-prevalence-increased-uptake-o
f-hormone-therapies-and-approval-of-novel-biologic
s-market/enquire-about-report
RESEARCH
No of Pages 250

5
RESEARCH
No of Pages 250